We are live on !
Find out more
SFCM
Seven Fleet Capital Management Portfolio holdings
AUM
$606M
Turnover
47.1%
This Fund
S&P 500
This Quarter Est. Return
+32.72%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$606M
AUM Growth
+$288M
(+90%)
Cap. Flow
+$198M
Cap. Flow % of AUM
Cap. Flow %
32.7%
Top 10 Holdings %
Top 10 Hldgs %
65.14%
Holding
138
New
23
Increased
43
Reduced
23
Closed
42
Avg Time Held
0.3
years
Top 10 Avg Time Held
0.2
years
Top 20 Avg Time Held
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CG Oncology
CGON
|
+$118M |
| 2 |
Tango Therapeutics
TNGX
|
+$67.4M |
| 3 |
Revolution Medicines
RVMD
|
+$23.6M |
| 4 |
Pharvaris
PHVS
|
+$18.2M |
| 5 |
Mirum Pharmaceuticals
MIRM
|
+$11.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tyra Biosciences
TYRA
|
+$7.49M |
| 2 |
Agios Pharmaceuticals
AGIO
|
+$4.63M |
| 3 |
Vaxcyte
PCVX
|
+$4.27M |
| 4 |
Soleno Therapeutics
SLNO
|
+$3.88M |
| 5 |
KalVista Pharmaceuticals
KALV
|
+$2.59M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.89% |
| 2 | Miscellaneous | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
CG Oncology
CGON
$6.56B
| $134M | 22.12% |
1,886,236
+1,810,478
| +2,390% | +$118M |
2025 Q4
2 quarters
|
|
|
2
Tango Therapeutics
TNGX
$4.43B
| $95.7M | 15.79% |
3,228,144
+2,726,132
| +543% | +$67.4M |
2025 Q4
2 quarters
|
|
|
3
Revolution Medicines
RVMD
$39.1B
| $45.3M | 7.48% |
242,029
+161,237
| +200% | +$23.6M |
2025 Q4
2 quarters
|
|
|
4
Pharvaris
PHVS
$2.39B
| $26.8M | 4.42% |
774,501
+601,770
| +348% | +$18.2M |
2025 Q4
2 quarters
|
|
5
Liquidia Corp
LQDA
$4.88B
| $20.5M | 3.38% |
256,603
+68,727
| +37% | +$3.68M |
2025 Q4
2 quarters
|
|
6
Enliven Therapeutics
ELVN
$3.79B
| $18.5M | 3.06% |
365,386
+201,356
| +123% | +$8.55M |
2025 Q4
2 quarters
|
|
7
Abivax
ABVX
$8.07B
| $14.8M | 2.45% |
111,334
+68,282
| +159% | +$7.73M |
2025 Q4
2 quarters
|
|
8
Avalo Therapeutics
AVTX
$481M
| $14.2M | 2.35% |
770,765
+556,946
| +260% | +$8.8M |
2025 Q4
2 quarters
|
|
|
9
Mirum Pharmaceuticals
MIRM
$6.18B
| $12.9M | 2.13% |
+110,393
| New | +$11.1M |
2026 Q2
0 quarters
|
|
10
Assembly Biosciences
ASMB
$459M
| $11.9M | 1.96% |
433,147
+377,000
| +671% | +$10.3M |
2025 Q4
2 quarters
|
|
11
Century Therapeutics
IPSC
$310M
| $10.7M | 1.76% |
4,347,826
+1,400,000
| +47% | +$3.2M |
2026 Q1
1 quarter
|
|
12
Cytokinetics
CYTK
$8.11B
| $10.1M | 1.66% |
118,240
+56,971
| +93% | +$4.09M |
2025 Q4
2 quarters
|
|
13
Taysha Gene Therapies
TSHA
$1.38B
| $9.9M | 1.64% |
1,504,400
+878,692
| +140% | +$5.2M |
2025 Q4
2 quarters
|
|
14
Veradermics Inc
MANE
$6.36B
| $9.8M | 1.62% |
+80,000
| New | +$7.49M |
2026 Q2
0 quarters
|
|
15
ArriVent BioPharma
AVBP
$665M
| $8.57M | 1.41% |
246,606
+196,354
| +391% | +$5.8M |
2026 Q1
1 quarter
|
|
16
Tarsus Pharmaceuticals
TARS
$3.78B
| $7.91M | 1.31% |
117,067
+97,267
| +491% | +$6.21M |
2025 Q4
2 quarters
|
|
17
Xencor
XNCR
$3.01B
| $7.83M | 1.29% |
368,305
+288,305
| +360% | +$3.6M |
2025 Q4
2 quarters
|
|
18
Roivant Sciences
ROIV
$30.4B
| $7.79M | 1.29% |
220,126
+91,958
| +72% | +$2.72M |
2026 Q1
1 quarter
|
|
19
Damora Therapeutics
DMRA
$1.47B
| $7.4M | 1.22% |
284,430
+183,182
| +181% | +$4.44M |
2026 Q1
1 quarter
|
|
20
Axsome Therapeutics
AXSM
$7.8B
| $7.06M | 1.16% |
28,826
+14,771
| +105% | +$3.2M |
2025 Q4
2 quarters
|
|
21
Definium Therapeutics
DFTX
$4.62B
| $6.99M | 1.15% |
148,647
+48,760
| +49% | +$1.2M |
2026 Q1
1 quarter
|
|
22
Dianthus Therapeutics
DNTH
$5.04B
| $6.31M | 1.04% |
64,723
+10,465
| +19% | +$914K |
2025 Q4
2 quarters
|
|
23
Cogent Biosciences
COGT
$5.16B
| $5.71M | 0.94% |
147,510
-1,889
| -1% | -$66.1K |
2025 Q4
2 quarters
|
|
24
Erasca
ERAS
$5.96B
| $5.64M | 0.93% |
308,007
+85,539
| +38% | +$1.22M |
2026 Q1
1 quarter
|
|
25
Protagonist Therapeutics
PTGX
$8.76B
| $5.57M | 0.92% |
45,400
+41,400
| +1,035% | +$4.32M |
2025 Q4
2 quarters
|
|
Similar funds
VV
CM
MCM
FRM
Seven Fleet Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Seven Fleet Capital Management held 138 positions worth $606M, up 90% from $318M the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Seven Fleet Capital Management deployed $198M of net new capital in Q2 2026, opening 23 new positions and adding to 43 existing holdings. Its largest new stake was Mirum Pharmaceuticals: 110,393 shares worth $12.9M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 56% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Agios Pharmaceuticals, an estimated $4.63M trimmed.
- Seven Fleet Capital Management's largest Q2 2026 buy was Mirum Pharmaceuticals: 110,393 shares worth $12.9M.
- Seven Fleet Capital Management added most to CG Oncology in Q2 2026, an estimated $118M increase.
- Seven Fleet Capital Management's biggest Q2 2026 reduction was Agios Pharmaceuticals, cutting an estimated $4.63M.
- Seven Fleet Capital Management fully exited Tyra Biosciences in Q2 2026, selling an estimated $7.49M.
- Seven Fleet Capital Management's ten largest holdings make up 65% of its $606M portfolio in Q2 2026.
- Seven Fleet Capital Management opened 23 new positions and closed 42 in Q2 2026.
- Seven Fleet Capital Management's portfolio value rose 90% quarter-over-quarter to $606M.
Based on Seven Fleet Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.